Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Plexpress and MediSapiens Launch OncoTRAC™ Gene Expression Service

Published: Tuesday, October 02, 2012
Last Updated: Tuesday, October 02, 2012
Bookmark and Share
Digital gene discovery integrated with targeted validation and in-depth analysis.

The companies have launched the new OncoTRAC™ Gene Expression Service, which takes advantage of MediSapiens’ extensive IST Online Gene Expression Database to facilitate the rapid, reliable identification of relevant genes of interest. After this initial discovery phase, the Plexpress FAST TRAC Gene Expression Analysis technology is used to assay the expression of a hand-selected 30-gene panel in a large number of samples.  The unique combination of these two complimentary approaches presents a complete solution from gene discovery through to validation and in-depth study, across a wide range of drug development, biomarker discovery and life science research applications.

Tommi Pisto, CEO of MediSapiens, commented: “With a database of over 20,000 samples and 300 million data points, our MediSapiens IST Online Gene Expression Viewer is the world’s largest unified gene expression database. The new OncoTRAC Service will allow users to leverage this data to discover new genes and then investigate their biological relevance.” Visualizing a gene’s function across all tissues and exploring relationships between expression and disease, the database allows the straightforward integration of proprietary data, whilst strict normalization also allows the comparison of results from a wide spectrum of studies. Exploration and identification of the most relevant genes of interest from a pool of samples of various cancer types, treatment-response and disease grades are subsequently compared with expression in healthy tissue, providing a knowledge-based discovery approach.

CEO of Plexpress, Dr Jari Rautio, said: “TRAC is the ideal technology for following up genomic discovery using the IST Online Gene Expression Viewer, as it allows the multiplex analysis of up to 30 genes in hundreds to thousands of samples. In this way, researchers can really investigate the biology of their system in considerable depth, without sacrificing the number of genes they can assay in each sample.” The other benefits of the fully automatable TRAC process include increased assay speed, as well as reduced technical variation, hands-on time and assay cost when compared with similar methods such as qPCR and microarray analysis. While TRAC offers the flexibility to create custom gene panels, pre-validated catalogue libraries are also available for specific applications such as ADME-Tox studies, ready for rapid, ‘off-the-shelf’ utilization.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Plexpress Announces Collaboration with Admescope
CRO to offer TRAC gene expression analysis for pre-clinical ADME-Tox studies.
Thursday, May 17, 2012
Plexpress Secures $2.3M to Commercialize TRAC High-Content Gene Expression Analysis Platform
Company targets applications including companion diagnostics and ADMET.
Thursday, April 19, 2012
Scientific News
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos